Innovent reworks deal with IASO; Granza raises $7M
Plus, news about Kvantify: China’s Innovent takes a stake in CAR-T partner: After bringing the BCMA CAR-T therapy Fucaso to market in China, Innovent and IASO Biotechnology are reworking their deal....
View ArticleCircle Pharma raises $54M as part of Series D while macrocycles heat up
Circle Pharma, a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D. The company recently closed the first part of the round, reeling in about $54...
View ArticleEli Lilly’s Alzheimer’s OK; GSK picks its mRNA bets; Megaround tally;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support
On the verge of raising its Series A in late 2021, Myricx Bio faced a tough choice. The toxicity profile for its IV and oral small molecules looked “like a key risk,” according to Myricx CEO Robin...
View ArticleVC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’
When Christopher Trummer tried raising money for his molecular glue degrader startup, he struggled to find VC support in his native Austria. The company, Celeris Therapeutics, had to leap to the US to...
View ArticleInventiva ramps up search for funding as cash runway erodes
As Inventiva continues to enroll patients into its Phase 3 liver disease program, it is seeking new funding to replenish its dwindling cash runway. The biotech had just €9.6 million ($10.4 million) in...
View ArticleClik here to view.
Lilly discloses its first biotech acquisition of the year, buying Morphic for...
Eli Lilly said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin drugs for chronic diseases, as the autoimmune space continues to drum up pharma...
View ArticleIdeaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397
Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain types of urothelial cancer and lung cancer. In...
View ArticleVanqua raises $45M; Aerovate to look for strategic alternatives
Plus, news about GSK, iTeos, Oxolife and SmallCella: Vanqua Bio reels in $45M: The Chicago neuroscience biotech extended its Series B, a spokesperson confirmed to Endpoints News. The company originally...
View ArticleClik here to view.
Gene insertion startup Komo Biosciences launches with new integrase...
Scientists at the University of Hawaii have improved tools for making large changes to genomes and have licensed the technology to a new startup called Komo Biosciences, its leaders told Endpoints News...
View ArticleClik here to view.
HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants
Takeda spinout HilleVax’s stock $HLVX sunk over 85% on Monday morning after the company announced its norovirus vaccine candidate failed a mid-stage trial in infants. While the vaccine, dubbed HIL-214,...
View ArticleInfections are major cause of non-relapse deaths after CAR-T cell therapy,...
A meta-analysis of CAR-T cell therapy studies found that just over half of cancer patient deaths that are not because of relapse are due to infections. “The main takeaway as clinicians is infections,...
View ArticleClik here to view.
Digital health deals rallied in the first half of 2024, though funding still...
Digital health startups raised $5.7 billion in the first half of 2024, slightly less than the $6.1 billion in the same period in 2023, according to venture and advisory firm Rock Health. But more...
View ArticleWhen can pharma companies correct online misinformation? FDA explains
The FDA on Monday laid out its latest expectations for how pharma companies can correct misinformation spreading online about their medical products. The draft guidance, which comes in the form of a...
View ArticleLilly bests Novo Nordisk in observational study of GLP-1 drugs
Patients receiving Eli Lilly’s diabetes medicine Mounjaro were “significantly more likely” to achieve clinically meaningful weight loss compared to those on Novo Nordisk’s Ozempic, according to a new...
View ArticleGilead's HIV drug patent battle with CDC continues with government appeal
The US government is appealing a jury’s decision that granted Gilead a major win in a patent fight over the company’s blockbuster HIV treatments Truvada and Descovy. Lawyers for the government last...
View ArticleRoche to reintroduce ocular implant two years after pulling it off the market
Roche plans to reintroduce Susvimo, its ocular implant pulled almost two years ago for manufacturing issues, in the coming weeks. In late 2022, the company’s Genentech unit withdrew the implant after a...
View ArticleAcquired biotech accuses Novartis of letting IL-15 asset 'wither on the vine'
Novartis is being accused of deliberately stalling the development of an acquired IL-15 asset, costing a smaller biotech up to $940 million in milestone payments plus additional damages and costs. The...
View ArticleClik here to view.
SciRhom secures €63M Series A for autoimmune disease program
SciRhom has raised €63 million ($70 million) in a Series A to advance its lead monoclonal antibody program through a first-in-human trial set to start in the second half of the year. The Phase 1 trial...
View ArticleBiovance debuts with €51M to lift up biotech scene in Portugal and southern...
Nearly a decade ago, Ricardo Perdigão Henriques’ colleagues balked at the idea of him leaving Boston to return home to Portugal to build a biotech ecosystem as a VC. “They said, ‘You’re crazy, Ricardo....
View Article